ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Use of patient-derived tumor organoid platform to predict the benefit of postoperative adjuvant chemotherapy for poor responders to neoadjuvant chemoradiotherapy in locally advanced rectal cancer

Xue, Weisong; Wang, Ting; Yao, Jiaxin; Wu, Wei; Chen, Dexin; Yan, Botao; Dong, Xiaoyu; Tang, Yuting; Zeng, Yunli; He, Yueyu; Cao, Peihua; Shao, Fangyuan; Huang, Wenhua*; Deng, Chuxia*; Yan, Jun*南方医科大学; 1
Bioengineering & Translational Medicine2023-11DOI: 10.1002/btm2.10586
1被引4阅读
引用收藏
分享

摘要

Postoperative adjuvant chemotherapy (AC) for poor responders to neoadjuvant chemoradiotherapy (nCRT) remains debatable among patients with locally advanced rectal cancer (LARC), necessitating biomarkers to accurately predict the benefits of AC. This study aimed to develop a patient-derived tumor organoid (PDTO) platform to predict the benefit of AC in LARC patients showing poor nCRT response. PDTOs were established using irradiated rectal cancer specimens with poor nCRT responses, and their sensitivity to chemotherapy regimens was tested. The half-maximal inhibitory concentration (IC50) value for the PDTO drug test was defined based on the clinical outcomes, and the accuracy of the PDTO prognostic predictions was calculated. Predictive models were developed and validated using the PDTO drug test results. Between October 2018 and December 2021, 86 PDTOs were successfully constructed from 138 specimens (success rate 62.3%). The optimal IC50 cut-off value for the organoid drug test was 39.31 mu mol/L, with a sensitivity of 84.75%, a specificity of 85.19%, and an accuracy of 84.88%. Multivariate Cox regression analysis revealed that the PDTO drug test was an independent predictor of prognosis. A nomogram based on the PDTO drug test was developed, showing good prognostic ability in predicting the 2-year and 3-year disease-free survivals (AUC of 0.826 [95% CI, 0.721-0.931] and 0.902 [95% CI, 0.823-0.982], respectively) and overall survivals (AUC of 0.859 [95% CI, 0.745-0.973] and 0.885 [95% CI, 0.792-0.978], respectively). The PDTO drug test can predict the benefit of postoperative AC in poor responders with LARC to nCRT.

学科与关键词

关键词
adjuvant chemotherapyneoadjuvant chemoradiotherapynomogramorganoidrectal cancer
相关
加载中…
  • Patient-Derived Tumor Organoids Can Predict the Progression-Free Survival of Patients With Stage IV Colorectal Cancer After Surgery
    Wang, Ting; Tang, Yuting; Pan, Wenjun; Yan, Botao; Hao, Yifan; Zeng, Yunli; Chen, Zexin; Lan, Jianqiang; Zhao, Shuhan; Deng, Chuxia; Zheng, Hang*; Yan, Jun*Diseases of the Colon and Rectum, 2023, 66(5): 733-743.被引 2
  • Accuracy of Using a Patient-Derived Tumor Organoid Culture Model to Predict the Response to Chemotherapy Regimens In Stage IV Colorectal Cancer A Blinded Study
    Wang, Ting; Pan, Wenjun; Zheng, Hang; Zheng, Hongping; Wang, Zhejun; Li, Jia J.; Deng, Chuxia; Yan, Jun*Diseases of the Colon and Rectum, 2021, 64(7): 833-850.被引 31
  • Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application
    Ren, Xiaoxue; Huang, Mingle; Weng, Weixiang; Xie, Yubin; Wu, Yifan; Zhu, Shenghua; Zhang, Ying; Li, Dongming; Lai, Jiaming; Shen, Shunli; Lin, Jie; Kuang, Ming; Li, Xiaoxing*; Yu, Jun*; Xu, Lixia*CELL REPORTS MEDICINE, 2023, 4(11): 101277.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
Bioengineering & Translational Medicine
发表日期
2023-11
卷期
第 8 卷, 第 6 期
页码
e10586
DOI
10.1002/btm2.10586
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82273360, 31972915, 32271181]; National Key Ramp;D Program of China [2022YFB4600600]; Guangdong Provincial Major Talents Project [2019JC05Y361]; Fu Jian Medical Innovation Project [2022CXA028]; Science and Technology Planning Project of Guangzhou City [202206010085]; China Postdoctoral Science Foundation [2020 M682789]; Clinical Research Project of Nanfang Hospital [2018CR034, 2020CR001, 2020CR011]; President Foundation of Nanfang Hospital, Southern Medical University [2019Z023]; Training Program for Undergraduate Innovation and Entrepreneurship [202212121011, S202212121092, S202212121104]; Guangdong Basic and Applied Basic Research Foundation [2020B1515120001]

作者

  • X

    Xue, Weisong (第一作者)

    1 · southern med univ · 2

  • W

    Wang, Ting

    1 · southern med univ

查看全部 15 位作者收起作者
  • Y

    Yao, Jiaxin

    1 · southern med univ

  • W

    Wu, Wei

    1 · southern med univ

  • C

    Chen, Dexin

    1 · southern med univ

  • Y

    Yan, Botao

    1 · southern med univ

  • D

    Dong, Xiaoyu

    1 · southern med univ

  • T

    Tang, Yuting

    1 · southern med univ

  • Z

    Zeng, Yunli

    1 · southern med univ

  • H

    He, Yueyu

    1 · southern med univ

  • C

    Cao, Peihua

    southern med univ

  • S

    Shao, Fangyuan

  • H

    Huang, Wenhua (通讯)

    southern med univ

  • D

    Deng, Chuxia (通讯)

  • Y

    Yan, Jun (通讯)

    southern med univ · 1

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417